26
|
Fitzgerald R, Owen R, Hargrave C, Pryor D, Lehman M, Bernard A, Mai T, Seshadri V, Fielding A. A Comparison of Non-coplanar Three-dimensional Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, and Volumetric Modulated Radiation Therapy for the Delivery of Stereotactic Ablative Radiation Therapy to Peripheral Lung Cancer. J Med Imaging Radiat Sci 2017; 48:360-369. [PMID: 31047471 DOI: 10.1016/j.jmir.2017.05.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Revised: 05/12/2017] [Accepted: 05/24/2017] [Indexed: 12/31/2022]
Abstract
AIM The objective of the study was to compare three noncoplanar delivery techniques (three-dimensional conformal radiation therapy [3DCRT], intensity-modulated radiation therapy [IMRT], and volumetric-modulated arc therapy [VMAT]) for the delivery of lung stereotactic ablative radiation therapy to peripheral lung tumours. METHODS AND MATERIALS The plans were compared by assessing the planning target volume coverage, doses to organs at risk, high and intermediate dose constraints (D2cm and R50%) and delivery times using analysis of variance for repeated measurements or Friedman's test when appropriate. RESULTS Mean PTV54 Gy coverage was found to be 95.6%, 95.7%, and 95.6% for the 3DCRT, IMRT, and VMAT techniques, respectively. No deviations to the intermediate dose constraints were found in 65%, 65%, and 85% of the patients for the 3DCRT, IMRT, and VMAT plans, respectively. Mean treatment times (excluding setup and imaging) were 20.0 minutes (±1.67), 25.2 minutes (±2.15), and 11.7 (±2.0) minutes respectively for 3DCRT, IMRT, and VMAT. CONCLUSION A noncoplanar VMAT technique was found to provide superior intermediate dose sparing with comparable prescription dose coverage when compared with noncoplanar 3DCRT or IMRT. In addition, VMAT was found to reduce the treatment times of stereotactic ablative radiation therapy delivery for peripheral lung tumours.
Collapse
|
27
|
Morris L, Thiruthaneeswaran N, Lehman M, Hasselburg G, Turner S. Are Future Radiation Oncologists Equipped With the Knowledge to Manage Elderly Patients With Cancer? Int J Radiat Oncol Biol Phys 2017; 98:743-747. [DOI: 10.1016/j.ijrobp.2017.01.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 12/21/2016] [Accepted: 01/01/2017] [Indexed: 01/07/2023]
|
28
|
Leung J, Lehman M. Radiation oncology directors of training survey 2016: Perspectives and challenges. J Med Imaging Radiat Oncol 2017; 61:791-796. [PMID: 28664678 DOI: 10.1111/1754-9485.12635] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2017] [Accepted: 05/12/2017] [Indexed: 12/01/2022]
Abstract
INTRODUCTION This paper reports the key findings of the first survey of Australian and New Zealand Radiation Oncology Directors of Training (DoTs) dealing with their perspectives, experiences and challenges. METHODS The survey was conducted in September 2016 using a 34-question instrument. It was emailed to all radiation oncology DoTs listed on the Royal Australian and New Zealand College of Radiologists (RANZCR) database. The questions related to demographics, protected time, weekly activities, support, the value of curriculum assessments, challenges and suggested improvements. Respondents were assured that their responses were anonymous. RESULTS The response rate was 59.6% (31/52). The median age of respondents was in the 41 to 45 age bracket, but nearly one quarter were over 45 years of age. The median time respondents had been in the role was three to five years (range <0.5 to >10) with the median number of trainees supervised being four (range 1-8). Thirty-five percent had a co DoT. DoTs spent a median of three hours per week on the role (range <1 to >8) with most respondents (67.7%) requiring time during and out of work performing the role, but ten percent claimed it was done out of hours only. Nearly all DoTs were aware they should have protected time, but only just half received it. The educational aspects of training dominated weekly activities, but rostering, specific trainee issues and administration were also featured. Time issues were the greatest challenge for respondents with clinical assignments the most challenging assessment. However, more emphasis on contouring and planning was thought to be required. All DoTs found the dedicated DoT workshops useful, but felt future discussions on trainees in difficulty could be emphasized. The vast majority felt supported by their training site and the College. All respondents believed in the role with most having an interest in educational activities. The majority of respondents (85%) intended to continue in the role for the next 1 to 2 years, but this dropped to 45% when asked about continuing for 5 years. CONCLUSIONS This survey of predominantly experienced DoTs, indicated that the role was deemed to be of value in delivering optimal training. The most significant challenges faced by DoTs were finding sufficient time to deal with the responsibilities of the role and dealing with underperforming trainees. Feedback on the currently employed work based assessments will be considered as FRO transitions into programmatic assessment. Furthermore, a desire for training in how to deal with trainees in difficulty, underperforming or unsuitable trainees is noted. Future work is planned following refinements of the survey instrument; and, will also explore stress and burnout in the DoT cohort.
Collapse
|
29
|
Morris L, Thiruthaneeswaran N, Lehman M, Hasselburg G, Turner S. EP-1407: Are future radiation oncologists equipped with the knowledge to manage elderly cancer patients? Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31842-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
30
|
Liu ESF, Wu VWC, Harris B, Foote M, Lehman M, Chan LWC. Vector-model-supported optimization in volumetric-modulated arc stereotactic radiotherapy planning for brain metastasis. Med Dosim 2017; 42:85-89. [PMID: 28318935 DOI: 10.1016/j.meddos.2017.01.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Revised: 09/15/2016] [Accepted: 01/18/2017] [Indexed: 10/19/2022]
Abstract
Long planning time in volumetric-modulated arc stereotactic radiotherapy (VMA-SRT) cases can limit its clinical efficiency and use. A vector model could retrieve previously successful radiotherapy cases that share various common anatomic features with the current case. The prsent study aimed to develop a vector model that could reduce planning time by applying the optimization parameters from those retrieved reference cases. Thirty-six VMA-SRT cases of brain metastasis (gender, male [n = 23], female [n = 13]; age range, 32 to 81 years old) were collected and used as a reference database. Another 10 VMA-SRT cases were planned with both conventional optimization and vector-model-supported optimization, following the oncologists' clinical dose prescriptions. Planning time and plan quality measures were compared using the 2-sided paired Wilcoxon signed rank test with a significance level of 0.05, with positive false discovery rate (pFDR) of less than 0.05. With vector-model-supported optimization, there was a significant reduction in the median planning time, a 40% reduction from 3.7 to 2.2 hours (p = 0.002, pFDR = 0.032), and for the number of iterations, a 30% reduction from 8.5 to 6.0 (p = 0.006, pFDR = 0.047). The quality of plans from both approaches was comparable. From these preliminary results, vector-model-supported optimization can expedite the optimization of VMA-SRT for brain metastasis while maintaining plan quality.
Collapse
|
31
|
Liu ESF, Wu VWC, Harris B, Lehman M, Pryor D, Chan LWC. Vector-model-supported approach in prostate plan optimization. Med Dosim 2017; 42:79-84. [PMID: 28318936 DOI: 10.1016/j.meddos.2017.01.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Accepted: 01/09/2017] [Indexed: 11/15/2022]
Abstract
Lengthy time consumed in traditional manual plan optimization can limit the use of step-and-shoot intensity-modulated radiotherapy/volumetric-modulated radiotherapy (S&S IMRT/VMAT). A vector model base, retrieving similar radiotherapy cases, was developed with respect to the structural and physiologic features extracted from the Digital Imaging and Communications in Medicine (DICOM) files. Planning parameters were retrieved from the selected similar reference case and applied to the test case to bypass the gradual adjustment of planning parameters. Therefore, the planning time spent on the traditional trial-and-error manual optimization approach in the beginning of optimization could be reduced. Each S&S IMRT/VMAT prostate reference database comprised 100 previously treated cases. Prostate cases were replanned with both traditional optimization and vector-model-supported optimization based on the oncologists' clinical dose prescriptions. A total of 360 plans, which consisted of 30 cases of S&S IMRT, 30 cases of 1-arc VMAT, and 30 cases of 2-arc VMAT plans including first optimization and final optimization with/without vector-model-supported optimization, were compared using the 2-sided t-test and paired Wilcoxon signed rank test, with a significance level of 0.05 and a false discovery rate of less than 0.05. For S&S IMRT, 1-arc VMAT, and 2-arc VMAT prostate plans, there was a significant reduction in the planning time and iteration with vector-model-supported optimization by almost 50%. When the first optimization plans were compared, 2-arc VMAT prostate plans had better plan quality than 1-arc VMAT plans. The volume receiving 35 Gy in the femoral head for 2-arc VMAT plans was reduced with the vector-model-supported optimization compared with the traditional manual optimization approach. Otherwise, the quality of plans from both approaches was comparable. Vector-model-supported optimization was shown to offer much shortened planning time and iteration number without compromising the plan quality.
Collapse
|
32
|
Hughes BG, Ahern E, Lehman M, Pratt G, Dauth M, Pritchard W, Wockner L, Horwood K. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study. Asia Pac J Clin Oncol 2017; 13:137-144. [PMID: 28181415 DOI: 10.1111/ajco.12649] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 08/19/2016] [Accepted: 09/06/2016] [Indexed: 12/28/2022]
Abstract
AIM Despite recent advances, outcomes for patients with stage III non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy (CRT) remain poor. We evaluated the combination of ciplatin/vinorelbine and concurrent thoracic radiotherapy followed by consolidation oral vinorelbine in this phase II study. METHODS Eligible patients with unresectable stage III NSCLC received cisplatin intravenous (IV) 40 mg/m2 and vinorelbine IV 20 mg/m2 on days 1, 8, 22 and 29 concurrent with thoracic radiotherapy of 60 Gy in 30 fractions. Four to eight weeks later, oral vinorelbine 60 mg/m2 day 1 and 8 every 3 weeks was given for 3 cycles. The primary end point was overall response rate (ORR). Secondary end points were safety, quality of life, progression-free survival (PFS) and overall survival (OS). RESULTS Twenty-seven eligible patients were enrolled from December 2007 to June 2010 before the trial was prematurely closed due to toxicity concerns. The median age was 63 years (range, 42-71), 56% were male, 52% ECOG 0 and 52% stage IIIa. The ORR was 81% (including 37% complete response rate) and disease control rate of 93%. The median PFS was 11 months and median OS was 26 months. Consolidation vinorelbine was associated with significant grade 3/4 toxicity (68%) including grade 3-5 febrile neutropenia (27%) and respiratory infections (36%) including two deaths in the consolidation phase (9%). CONCLUSIONS Consolidation oral vinorelbine after CRT was associated with significant toxicity. Overall, this regimen achieved a high ORR and survival results comparable to other CRT protocols but the significant toxicity precludes further evaluation of this approach.
Collapse
|
33
|
Huo M, Gorayski P, Pinkham MB, Lehman M. Advances in radiotherapy technology for non-small cell lung cancer: What every general practitioner should know. AUSTRALIAN FAMILY PHYSICIAN 2016; 45:805-809. [PMID: 27806449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
BACKGROUND Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death in Australia. Radiotherapy plays an important role in the curative and palliative settings. OBJECTIVE This article reviews recent technological advances that have expanded the radiotherapy treatment options available, and presents standard and emerging approaches to NSCLC. DISCUSSION General practitioners play an integral role in the care and education of patients during diagnosis, treatment and
follow-up of NSCLC. Stereotactic (ablative) body radiotherapy,
intensity-modulated radiotherapy, intracranial radiosurgery and hippocampal-avoidance whole-brain radiotherapy are discussed in this article.
Collapse
|
34
|
Lehman M, Gorayski P, Watson S, Edeling D, Jackson J, Whitty J. Patient preferences regarding prophylactic cranial irradiation: A discrete choice experiment. Radiother Oncol 2016; 121:225-231. [PMID: 27717511 DOI: 10.1016/j.radonc.2016.09.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2016] [Revised: 08/29/2016] [Accepted: 09/11/2016] [Indexed: 12/28/2022]
Abstract
INTRODUCTION In patients with non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT), prophylactic cranial irradiation (PCI) is not standard practice. This study determined patient preferences for PCI with respect to survival benefit, reduction in brain metastases (BM) and acceptable toxicity. METHODS A Discrete Choice Experiment was completed pre- and post-treatment. Patients made 15 hypothetical choices between two alternative PCI treatments described by four attributes: amount of life gained, chance of BM, ability to care for oneself, and loss of memory. Participants also chose between PCI and no PCI. RESULTS 54 and 46 surveys were completed pre- and post-treatment. The most important attributes pre-treatment were: a survival benefit >6months, of 3-6months, avoiding severe problems with memory and self-care, avoiding quite a bit of difficulty with memory and maximally reducing BM recurrence. Post-treatment, BM reduction became more important. 90% of patients would accept PCI for a survival benefit >6months, with a maximal reduction in BM even if severe memory/self-care problems occurred. With a 10% reduction in BM and mild problems with memory and self-care 70% of patients pre- (90% post-treatment) would accept PCI for a survival benefit of 1-3months, and 52% pre- (78% post-treatment) for no survival benefit. CONCLUSION Improvement in survival is the most important attribute of PCI with patients willing to accept significant toxicity for maximum survival and less toxicity for less survival benefit. BM reduction became more important after treatment. The majority of patients would accept PCI for no survival benefit and a reduction in BM.
Collapse
|
35
|
Dwyer PM, Lao L, Ruben JD, Yap ML, Siva S, Hegi-Johnson F, Hardcastle N, Barber J, Lehman M, Ball D, Vinod SK. Australia and New Zealand Faculty of Radiation Oncology Lung Interest Cooperative: 2015 consensus guidelines for the use of advanced technologies in the radiation therapy treatment of locally advanced non-small cell lung cancer. J Med Imaging Radiat Oncol 2016; 60:686-692. [PMID: 27470188 DOI: 10.1111/1754-9485.12501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Accepted: 06/26/2016] [Indexed: 11/28/2022]
|
36
|
Nicholls L, Keir GJ, Murphy MA, Mai T, Lehman M. Prophylactic cranial irradiation in small cell lung cancer: A single institution experience. Asia Pac J Clin Oncol 2016; 12:415-420. [PMID: 27453519 DOI: 10.1111/ajco.12564] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Revised: 09/01/2015] [Accepted: 12/27/2015] [Indexed: 11/28/2022]
Abstract
AIM To compare patient demographics, prophylactic cranial irradiation (PCI) utilization and overall survival (OS) of patients with small cell lung cancer (SCLC) referred to a large tertiary center with those reported in large clinical trials. PATIENTS AND METHODS A retrospective review was conducted of consecutive patients with limited stage (LS) and extensive stage (ES) SCLC diagnosed at the Princess Alexandra Hospital between January 2008 and December 2013. RESULTS Two hundred and three patients with a mean age of 65.4 (±10.7) years were followed for a median duration of 7.6 months (range 0.5-76.5). At diagnosis, 129 (64%) patients had ES-SCLC, including 39 (19.2%) with cerebral metastases. Median OS in LS-SCLC patients receiving PCI was 18.8 months (0.9-69.4), compared with 8.2 months (0.1-34.4) in patients who did not receive PCI (P < 0.001). Median OS in the ES-SCLC cohort receiving PCI was 13.6 months (5.2-37.5) compared to 5.6 months (0.1-73.6) in patients who did not receive the therapy (P < 0.001). There was a significant improvement in intracranial disease-free survival of 7.1 months in patients with ES-SCLC who received PCI. Forty-two LS-SCLC patients (57%) did not receive PCI due to patient suitability. CONCLUSIONS In our SCLC cohort, median OS following PCI in LS-SCLC and ES-SCLC is comparable to published data. PCI use at our institution was lower than utilization rates in large meta-analyses, predominately due to poor chemotherapy tolerance and patient suitability. This may be more representative of patients treated in clinical practice rather than those recruited into large phase III trials.
Collapse
|
37
|
Abstract
BACKGROUND Breast-conserving therapy for women with breast cancer consists of local excision of the tumour (achieving clear margins) followed by radiotherapy (RT). RT is given to sterilize tumour cells that may remain after surgery to decrease the risk of local tumour recurrence. Most true recurrences occur in the same quadrant as the original tumour. Whole breast radiotherapy (WBRT) may not protect against the development of a new primary cancer developing in other quadrants of the breast. In this Cochrane review, we investigated the delivery of radiation to a limited volume of the breast around the tumour bed (partial breast irradiation (PBI)) sometimes with a shortened treatment duration (accelerated partial breast irradiation (APBI)). OBJECTIVES To determine whether PBI/APBI is equivalent to or better than conventional or hypo-fractionated WBRT after breast-conserving therapy for early-stage breast cancer. SEARCH METHODS We searched the Cochrane Breast Cancer Group Specialized Register (4 May 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) (2015, Issue 5), MEDLINE (January 1966 to 4 May 2015), EMBASE (1980 to 4 May 2015), CINAHL (4 May 2015) and Current Contents (4 May 2015). We searched the International Standard Randomised Controlled Trial Number Register (5 May 2015), the World Health Organization's International Clinical Trials Registry Platform (4 May 2015) and ClinicalTrials.gov (17 June 2015). We searched for grey literature: OpenGrey (17 June 2015), reference lists of articles, several conference proceedings and published abstracts, and applied no language restrictions. SELECTION CRITERIA Randomized controlled trials (RCTs) without confounding, that evaluated conservative surgery plus PBI/APBI versus conservative surgery plus WBRT. Published and unpublished trials were eligible. DATA COLLECTION AND ANALYSIS Two review authors (BH and ML) performed data extraction and used Cochrane's 'Risk of bias' tool, and resolved any disagreements through discussion. We entered data into Review Manager 5 for analysis. MAIN RESULTS We included seven RCTs and studied 7586 women of the 8955 enrolled.Local recurrence-free survival appeared worse for women receiving PBI/APBI compared to WBRT (hazard ratio (HR) 1.62, 95% confidence interval (CI) 1.11 to 2.35; six studies, 6820 participants, low-quality evidence). Cosmesis (physician-reported) appeared worse with PBI/APBI (odds ratio (OR) 1.51, 95% CI 1.17 to 1.95, five studies, 1720 participants, low-quality evidence). Overall survival did not differ with PBI/APBI (HR 0.90, 95% CI 0.74 to 1.09, five studies, 6718 participants, high-quality evidence).Late radiation toxicity (subcutaneous fibrosis) appeared worse with PBI/APBI (OR 6.58, 95% CI 3.08 to 14.06, one study, 766 participants, moderate-quality evidence). Acute skin toxicity appeared reduced with PBI/APBI (OR 0.04, 95% CI 0.02 to 0.09, two studies, 608 participants). Telangiectasia (OR 26.56, 95% CI 3.59 to 196.51, 1 study, 766 participants) and radiological fat necrosis (OR 1.58, 95% CI 1.02 to 2.43, three studies, 1319 participants) appeared worse with PBI/APBI. Late skin toxicity (OR 0.21, 95% CI 0.01 to 4.39, two studies, 608 participants) and breast pain (OR 2.17, 95% CI 0.56 to 8.44, one study, 766 participants) appeared not to differ with PBI/APBI.'Elsewhere primaries' (new primaries in the ipsilateral breast) appeared more frequent with PBI/APBI (OR 3.97, 95% CI 1.51 to 10.41, three studies, 3009 participants).We found no clear evidence of a difference for the comparison of PBI/APBI with WBRT for the outcomes of: cause-specific survival (HR 1.08, 95% CI 0.73 to 1.58, five studies, 6718 participants, moderate-quality evidence), distant metastasis-free survival (HR 0.94, 95% CI 0.65 to 1.37, four studies, 3267 participants, moderate-quality evidence), relapse-free survival (HR 1.36, 95% CI 0.88 to 2.09, three studies, 3811 participants), loco-regional recurrence-free survival (HR 1.80, 95% CI 1.00 to 3.25, two studies, 3553 participants) or mastectomy rates (OR 1.20, 95% CI 0.77 to 1.87, three studies, 4817 participants, low-quality evidence). Compliance was met: more than 90% of the women in all studies received the RT they were assigned to receive. We found no data for the outcomes of costs, quality of life or consumer preference. AUTHORS' CONCLUSIONS It appeared that local recurrence and 'elsewhere primaries' (new primaries in the ipsilateral breast) are increased with PBI/APBI (the difference was small), but we found no evidence of detriment to other oncological outcomes. It appeared that cosmetic outcomes and some late effects were worse with PBI/APBI but its use was associated with less acute skin toxicity. The limitations of the data currently available mean that we cannot make definitive conclusions about the efficacy and safety or ways to deliver of PBI/APBI. We await completion of ongoing trials.
Collapse
|
38
|
Hickey BE, James ML, Lehman M, Hider PN, Jeffery M, Francis DP, See AM. Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev 2016; 7:CD003860. [PMID: 27425588 PMCID: PMC6457862 DOI: 10.1002/14651858.cd003860.pub4] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Shortening the duration of radiation therapy would benefit women with early breast cancer treated with breast conserving surgery. It may also improve access to radiation therapy by improving efficiency in radiation oncology departments globally. This can only happen if the shorter treatment is as effective and safe as conventional radiation therapy. This is an update of a Cochrane Review first published in 2008 and updated in 2009. OBJECTIVES To assess the effect of altered radiation fraction size for women with early breast cancer who have had breast conserving surgery. SEARCH METHODS We searched the Cochrane Breast Cancer Specialised Register (23 May 2015), CENTRAL (The Cochrane Library 2015, Issue 4), MEDLINE (Jan 1996 to May 2015), EMBASE (Jan 1980 to May 2015), the WHO International Clinical Trials Registry Platform (ICTRP) search portal (June 2010 to May 2015) and ClinicalTrials.gov (16 April 2015), reference lists of articles and relevant conference proceedings. No language or publication constraints were applied. SELECTION CRITERIA Randomised controlled trials of altered fraction size versus conventional fractionation for radiation therapy in women with early breast cancer who had undergone breast conserving surgery. DATA COLLECTION AND ANALYSIS Two authors performed data extraction independently, with disagreements resolved by discussion. We sought missing data from trial authors. MAIN RESULTS We studied 8228 women in nine studies. Eight out of nine studies were at low or unclear risk of bias. Altered fraction size (delivering radiation therapy in larger amounts each day but over fewer days than with conventional fractionation) did not have a clinically meaningful effect on: local recurrence-free survival (Hazard Ratio (HR) 0.94, 95% CI 0.77 to 1.15, 7095 women, four studies, high-quality evidence), cosmetic outcome (Risk ratio (RR) 0.90, 95% CI 0.81 to 1.01, 2103 women, four studies, high-quality evidence) or overall survival (HR 0.91, 95% CI 0.80 to 1.03, 5685 women, three studies, high-quality evidence). Acute radiation skin toxicity (RR 0.32, 95% CI 0.22 to 0.45, 357 women, two studies) was reduced with altered fraction size. Late radiation subcutaneous toxicity did not differ with altered fraction size (RR 0.93, 95% CI 0.83 to 1.05, 5130 women, four studies, high-quality evidence). Breast cancer-specific survival (HR 0.91, 95% CI 0.78 to 1.06, 5685 women, three studies, high quality evidence) and relapse-free survival (HR 0.93, 95% CI 0.82 to 1.05, 5685 women, three studies, moderate-quality evidence) did not differ with altered fraction size. We found no data for mastectomy rate. Altered fraction size was associated with less patient-reported (P < 0.001) and physician-reported (P = 0.009) fatigue at six months (287 women, one study). We found no difference in the issue of altered fractionation for patient-reported outcomes of: physical well-being (P = 0.46), functional well-being (P = 0.38), emotional well-being (P = 0.58), social well-being (P = 0.32), breast cancer concerns (P = 0.94; 287 women, one study). We found no data with respect to costs. AUTHORS' CONCLUSIONS We found that using altered fraction size regimens (greater than 2 Gy per fraction) does not have a clinically meaningful effect on local recurrence, is associated with decreased acute toxicity and does not seem to affect breast appearance, late toxicity or patient-reported quality-of-life measures for selected women treated with breast conserving therapy. These are mostly women with node negative tumours smaller than 3 cm and negative pathological margins.
Collapse
|
39
|
Islam SM, Vinod SK, Lehman M, Siva S, Kron T, Dwyer PM, Holloway L, Lao L, Yap ML, Ruben JD. Lung cancer radiation therapy in Australia and New Zealand: Patterns of practice. J Med Imaging Radiat Oncol 2016; 60:677-685. [DOI: 10.1111/1754-9485.12475] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 04/24/2016] [Indexed: 12/25/2022]
|
40
|
Turner S, Lehman M. Are we training the next generation of proficient radiation oncologists, or just better examination candidates? J Med Imaging Radiat Oncol 2016; 60:389-92. [DOI: 10.1111/1754-9485.12457] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Accepted: 03/04/2016] [Indexed: 11/29/2022]
|
41
|
Lehman M. Improving Therapeutic Outcomes in Non-small Cell Lung Cancer not Suitable for Curative Intent Therapy — A Review of the Role of Radiation Therapy in an Era of Increasing Systemic Therapy Options. Clin Oncol (R Coll Radiol) 2016; 28:327-33. [DOI: 10.1016/j.clon.2015.11.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Revised: 10/23/2015] [Accepted: 10/26/2015] [Indexed: 01/27/2023]
|
42
|
Fitzgerald R, Owen R, Barry T, Hargrave C, Pryor D, Bernard A, Lehman M, Mai T, Fielding A. The effect of beam arrangements and the impact of non-coplanar beams on the treatment planning of stereotactic ablative radiation therapy for early stage lung cancer. J Med Radiat Sci 2016; 63:31-40. [PMID: 27087973 PMCID: PMC4775835 DOI: 10.1002/jmrs.118] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Revised: 03/30/2015] [Accepted: 06/10/2015] [Indexed: 12/25/2022] Open
Abstract
INTRODUCTION The aim of this study was to compare various coplanar and non-coplanar 3-dimensional conformal radiation therapy (3DCRT) beam arrangements for the delivery of stereotactic ablative radiation therapy (SABR) to patients with early stage lung cancer, based on the dosimetric criteria from the Radiation Therapy Oncology Group (RTOG) 1021 protocol. METHODS Ten medically inoperable lung cancer patients eligible for SABR were re-planned using three different coplanar and three different non-coplanar beam arrangements. The plans were compared by assessing planning target volume (PTV) coverage, doses to normal tissues, the high-dose conformity (conformity index) and intermediate dose spillage as defined by the D2cm, (the dose at any point 2 cm away from the PTV), and the R50% (the ratio of the volume of half the prescription dose to the volume of the PTV). RESULTS Sixty plans in total were assessed. Mean PTV coverage with the prescription isodose was similar between coplanar (95.14%) and non-coplanar (95.26%) techniques (P = 0.47). There was significant difference between all coplanar and all non-coplanar fields for the R50% (P < 0.0001) but none for the D2cm (P = 0.19). The seven and nine field beam arrangements with two non-coplanar fields had less unacceptable protocol deviations (10 and 7) than the seven and nine field plans with only coplanar fields (13 and 8). The 13 field coplanar fields did not improve protocol compliance with eight unacceptable deviations. The 10 field non-coplanar beam arrangement achieved best compliance with the RTOG 1021 dose criteria with only one unacceptable deviation (maximum rib dose). CONCLUSION A 3DCRT planning technique using 10 fields with ≥6 non-coplanar beams best satisfied high and intermediate dose constraints stipulated in the RTOG 1021 trial. Further investigations are required to determine if minor protocol deviations should be balanced against efficiency with the extended treatment times required to deliver non-coplanar fields and if treatment times can be improved using novel intensity modulated techniques.
Collapse
|
43
|
Fitzgerald R, Owen R, Hargrave C, Pryor D, Barry T, Lehman M, Bernard A, Mai T, Seshadri V, Fielding A. A comparison of three different VMAT techniques for the delivery of lung stereotactic ablative radiation therapy. J Med Radiat Sci 2016; 63:23-30. [PMID: 27087972 PMCID: PMC4775834 DOI: 10.1002/jmrs.156] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Revised: 10/20/2015] [Accepted: 12/13/2015] [Indexed: 02/03/2023] Open
Abstract
INTRODUCTION The purpose of this study was to investigate coplanar and non-coplanar volumetric modulated arc therapy (VMAT) delivery techniques for stereotactic ablative radiation therapy (SABR) to the lung. METHODS For ten patients who had already completed a course of radiation therapy for early stage lung cancer, three new SABR treatment plans were created using (1) a coplanar full arc (FA) technique, (2) a coplanar partial arc technique (PA) and (3) a non-coplanar technique utilising three partial arcs (NCA). These plans were evaluated using planning target volume (PTV) coverage, dose to organs at risk, and high and intermediate dose constraints as incorporated by radiation therapy oncology group (RTOG) 1021. RESULTS When the FA and PA techniques were compared to the NCA technique, on average the PTV coverage (V 54Gy) was similar (P = 0.15); FA (95.1%), PA (95.11%) and NCA (95.71%). The NCA resulted in a better conformity index (CI) of the prescription dose (0.89) when compared to the FA technique (0.88, P = 0.23) and the PA technique (0.83, P = 0.06). The NCA technique improved the intermediate dose constraints with a statistically significant difference for the D 2cm and R 50% when compared with the FA (P < 0.03 and <0.0001) and PA (P < 0.04 and <0.0001) techniques. The NCA technique reduced the maximum spinal cord dose by 2.72 and 4.2 Gy when compared to the PA and FA techniques respectively. Mean lung doses were 4.09, 4.31 and 3.98 Gy for the FA, PA and NCA techniques respectively. CONCLUSION The NCA VMAT technique provided the highest compliance to RTOG 1021 when compared to coplanar techniques for lung SABR. However, single FA coplanar VMAT was suitable for 70% of patients when minor deviations to both the intermediate dose and organ at risk (OAR) constraints were accepted.
Collapse
|
44
|
Gorayski P, Pinkham MB, Lehman M. Advances in radiotherapy technology for prostate cancer: What every GP should know. AUSTRALIAN FAMILY PHYSICIAN 2015; 44:663-667. [PMID: 26488048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND One in five Australian men are diagnosed with prostate cancer. External beam radiation therapy (EBRT) is an effective treatment for men suitable for definitive therapy. OBJECTIVE This article outlines the processes involved in EBRT for prostate cancer, with particular emphasis on recent technological advances that have had a positive impact on patient outcomes. The patient's experience is explained and comparisons are made with surgery. DISCUSSION Patients diagnosed with localised prostate cancer may have multiple treatment options. General practitioners have an important role in helping patients navigate their way through the information needed to make this decision. Radiotherapy technologies, including image guidance, intensity-modulated radiation therapy and stereotactic (ablative) radiation therapy are discussed in this article.
Collapse
|
45
|
Campbell A, Owen R, Brown E, Pryor D, Bernard A, Lehman M. Evaluating the accuracy of the XVI dual registration tool compared with manual soft tissue matching to localise tumour volumes for post-prostatectomy patients receiving radiotherapy. J Med Imaging Radiat Oncol 2015; 59:527-534. [PMID: 26109083 DOI: 10.1111/1754-9485.12332] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2014] [Accepted: 05/06/2015] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Cone beam computerised tomography (CBCT) enables soft tissue visualisation to optimise matching in the post-prostatectomy setting, but is associated with inter-observer variability. This study assessed the accuracy and consistency of automated soft tissue localisation using XVI's dual registration tool (DRT). METHODS Sixty CBCT images from ten post-prostatectomy patients were matched using: (i) the DRT and (ii) manual soft tissue registration by six radiation therapists (RTs). Shifts in the three Cartesian planes were recorded. The accuracy of the match was determined by comparing shifts to matches performed by two genitourinary radiation oncologists (ROs). A Bland-Altman method was used to assess the 95% levels of agreement (LoA). A clinical threshold of 3 mm was used to define equivalence between methods of matching. RESULTS The 95% LoA between DRT-ROs in the superior/inferior, left/right and anterior/posterior directions were -2.21 to +3.18 mm, -0.77 to +0.84 mm, and -1.52 to +4.12 mm, respectively. The 95% LoA between RTs-ROs in the superior/inferior, left/right and anterior/posterior directions were -1.89 to +1.86 mm, -0.71 to +0.62 mm and -2.8 to +3.43 mm, respectively. Five DRT CBCT matches (8.33%) were outside the 3-mm threshold, all in the setting of bladder underfilling or rectal gas. The mean time for manual matching was 82 versus 65 s for DRT. CONCLUSIONS XVI's DRT is comparable with RTs manually matching soft tissue on CBCT. The DRT can minimise RT inter-observer variability; however, involuntary bladder and rectal filling can influence the tools accuracy, highlighting the need for RT evaluation of the DRT match.
Collapse
|
46
|
Gorayski P, Pinkham MB, Lehman M. Reply - Advances in radiotherapy: Ensuring balance in the discussion. AUSTRALIAN FAMILY PHYSICIAN 2015; 44:777-778. [PMID: 28471150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
|
47
|
Trinh H, Pinkham MB, Lehman M, Zarate D, Dauth M, McGrath M, McCaffrey E, Mai GT, Horwood K. Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy. CLINICAL RESPIRATORY JOURNAL 2014; 10:428-34. [PMID: 25353367 DOI: 10.1111/crj.12233] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Revised: 09/13/2014] [Accepted: 10/27/2014] [Indexed: 12/25/2022]
Abstract
BACKGROUND AND AIM Thoracic radiotherapy administered concurrently with chemotherapy is the standard of care for patients with inoperable stage III non-small cell lung cancer, but the optimal chemotherapy regimen is not clearly established. The objective of this study was to assess outcomes in a large cohort of patients treated with curative-intent using carboplatin and paclitaxel. METHODS Consecutive patients undergoing curative-intent radiotherapy to 60-66 Gy in 30-33 daily fractions with concurrent weekly carboplatin (AUC = 2) and paclitaxel (45 mg/m(2) /week) between March 2004 and May 2012 were identified from a prospective database and reviewed individually. A minimum follow-up of 3 months was required unless death occurred sooner. Response to treatment was defined according to established guidelines on re-staging computed tomography scan at 3 months. Toxicities were assessed using a standardised scoring system. RESULTS One hundred and seven patients were analysed. The median follow-up was 43.5 months. Three months after treatment, a complete or partial response was observed in 72 patients (68%), and nine patients (8%) had already died. The overall locoregional failure rate was 47%, and failure eventually occurred at any site in 75 patients (70%). Median progression-free survival, and median survival were 15 and 22 months, respectively. Grade 3-4 neutropaenia, thrombocytopaenia, nephrotoxicity, oesophagitis and pneumonitis were observed in 15%, 1%, 3%, 11% and 9% of patients during treatment, respectively. There was one episode of fatal radiation pneumonitis. CONCLUSION Treatment with thoracic radiotherapy and concurrent carboplatin and paclitaxel chemotherapy is feasible. Survival and toxicity outcomes compare favorably to those reported using cisplatin-based regimens.
Collapse
|
48
|
Loh J, Jovanovic L, Lehman M, Capp A, Pryor D, Harris M, Nelson C, Martin J. Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J Cancer Res Clin Oncol 2014; 140:2157-62. [DOI: 10.1007/s00432-014-1775-3] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Accepted: 07/04/2014] [Indexed: 11/30/2022]
|
49
|
Abstract
BACKGROUND Breast conserving therapy for women with breast cancer consists of local excision of the tumour (achieving clear margins) followed by radiation therapy (RT). RT is given to sterilize tumour cells that may remain after surgery to decrease the risk of local tumour recurrence. Most true recurrences occur in the same quadrant as the original tumour. Whole breast RT may not protect against the development of a new primary cancer developing in other quadrants of the breast. In this Cochrane Review, we investigated the role of delivering radiation to a limited volume of the breast around the tumour bed (partial breast irradiation: PBI) sometimes with a shortened treatment duration (accelerated partial breast irradiation: APBI). OBJECTIVES To determine whether PBI/APBI is equivalent to or better than conventional or hypofractionated WBRT after breast conservation therapy for early-stage breast cancer. SEARCH METHODS We searched the Cochrane Breast Cancer Group Specialised Register (07 November 2013), CENTRAL (2014, Issue 3), MEDLINE (January 1966 to 11 April 2014), EMBASE (1980 to 11 April 2014), CINAHL (11 April 2014) and Current Contents (11 April 2014). Also we searched the International Standard Randomised Controlled Trial Number Register, the World Health Organization's International Clinical Trials Registry Platform (07 November 2013) and US clinical trials registry (www.clinicaltrials.gov) (22 April 2014). We searched for grey literature: Open Grey (23 April 2014), reference lists of articles, a number of conference proceedings and published abstracts, and did not apply any language restrictions. SELECTION CRITERIA Randomised controlled trials (RCTs) without confounding and evaluating conservative surgery plus PBI/APBI versus conservative surgery plus whole breast RT. We included both published and unpublished trials. DATA COLLECTION AND ANALYSIS Three review authors (ML, DF and BH) performed data extraction and resolved any disagreements through discussion. We entered data into Review Manager for analysis. BH and ML assessed trials, graded the methodological quality using Cochrane's Risk of Bias tool and resolved any disagreements through discussion. MAIN RESULTS We included four RCTs that had 2253 women. Two older trials examined RT techniques which do not reflect current practice and one trial had a short follow-up. We downgraded the quality of the evidence for our key outcomes due to risk of bias. Taken together with other GRADE recommendations, the quality of evidence for our outcomes was very low to low. For the comparison of partial breast irradiation/accelerated breast irradiation (PBI/APBI) with whole breast irradiation (WBRT), local recurrence-free survival appeared worse (Hazard Ratio (HR) 1.74, 95% confidence interval (CI) 1.23 to 2.45; three trials, 1140 participants, very low quality evidence). Cosmesis appeared improved with PBI/APBI in a single trial (OR 0.40, 95% CI 0.23 to 0.72; one trial, 241 participants, very low quality evidence), but late toxicity (telangiectasia OR 4.41, 95% CI 3.21 to 6.05; very low quality evidence, 708 participants) and subcutaneous fibrosis (OR 4.27, 95% CI 3.04 to 6.01; one trial, 710 participants, very low quality evidence) appeared increased in another trial. We found no clear evidence of a difference for the comparison of PBI/APBI versus WBRT for the outcomes of: overall survival (HR 0.99, 95% CI 0.83 to 1.18; three trials, 1140 participants, very low quality evidence), cause-specific survival (HR 0.95, 95% CI 0.74 to 1.22; two trials, 966 participants, low evidence quality), distant metastasis-free survival (HR 1.02, 95% CI 0.81 to 1.28; 1140 participants, low quality evidence), subsequent mastectomy rate (OR 0.20, 95% CI 0.01 to 4.21; 258 participants, low quality evidence) and relapse-free survival (HR 0.99, 95% CI 0.53 to 1.85; 258 participants, low quality evidence). We found no data for the outcomes of acute toxicity, new ipsilateral breast primaries, costs, quality of life or consumer preference. AUTHORS' CONCLUSIONS The limitations of the data currently available mean that we cannot make definitive conclusions about the efficacy and safety or ways to deliver of PBI/APBI. We await completion of ongoing trials.
Collapse
|
50
|
Foroudi F, Pham D, Rolfo A, Bressel M, Tang CI, Tan A, Turner S, Hruby G, Williams S, Hayne D, Lehman M, Skala M, Jose CC, Gogna K, Kron T. The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. Radiother Oncol 2014; 111:316-20. [DOI: 10.1016/j.radonc.2014.02.015] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Revised: 12/31/2013] [Accepted: 02/12/2014] [Indexed: 11/29/2022]
|